Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. Bonotto, M., Gerratana, L., Di Maio, M., De Angelis, C., Cinausero, M., Moroso, S., Milano, M., Stanzione, B., Gargiulo, P., Iacono, D., Minisini, A. M., Mansutti, M., Fasola, G., De Placido, S., Arpino, G., & Puglisi, F. The Breast, 31:114–120, February, 2017.
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis [link]Paper  doi  bibtex   
@article{bonotto_chemotherapy_2017,
	title = {Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like {HER2}-negative metastatic breast cancer: {A} propensity score analysis},
	volume = {31},
	issn = {09609776},
	shorttitle = {Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like {HER2}-negative metastatic breast cancer},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S0960977616302041},
	doi = {10.1016/j.breast.2016.10.021},
	language = {en},
	urldate = {2021-09-15},
	journal = {The Breast},
	author = {Bonotto, Marta and Gerratana, Lorenzo and Di Maio, Massimo and De Angelis, Carmine and Cinausero, Marika and Moroso, Stefano and Milano, Monica and Stanzione, Brigida and Gargiulo, Piera and Iacono, Donatella and Minisini, Alessandro Marco and Mansutti, Mauro and Fasola, Gianpiero and De Placido, Sabino and Arpino, Grazia and Puglisi, Fabio},
	month = feb,
	year = {2017},
	pages = {114--120},
}

Downloads: 0